
MMJ BioPharma Labs recently became one of the only federally authorized labs dedicated to cannabis extraction, research, and development with their approved DEA Analytical Lab Registration for schedule 1-4 drugs.
The company's primary focus is on cannabis research and development. MMJ BioPharma Labs will be assisting MMJ International Holdings in the research and development of its proprietary gel cap medicine, for the eventual FDA approval of its medicines MMJ 001 and MMJ 002 to treat multiple sclerosis and Huntington's disease. Clinical trials will begin soon.